The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
Bivalent Omicron BA. 1–Adapted BNT162b2 booster in adults older than 55 years
P Winokur, J Gayed, D Fitz-Patrick… - … England Journal of …, 2023 - Mass Medical Soc
Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide …
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Summary Background Several SARS-CoV-2 variants of concern have been identified that
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …
[HTML][HTML] Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron
variant, designated as a variant of concern by the World Health Organization, carries …
variant, designated as a variant of concern by the World Health Organization, carries …
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
Current coronavirus disease 2019 (COVID-19) vaccines effectively reduce overall morbidity
and mortality and are vitally important to controlling the pandemic. Individuals who …
and mortality and are vitally important to controlling the pandemic. Individuals who …
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
M Lipsitch, F Krammer, G Regev-Yochay… - Nature Reviews …, 2022 - nature.com
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
Waning immunity after the BNT162b2 vaccine in Israel
Abstract Background In December 2020, Israel began a mass vaccination campaign against
coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to …
coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to …